ES Time: your reliable partner for successful investments
ES Time is a licensed brokerage firm that aims to assist clients in achieving profitable investments as a means to safeguard and grow their capital. The company prides itself on offering optimal trading conditions, enabling clients to earn returns with minimal investments and enjoy swift order execution. Currently, ES Time serves over 130,000 individuals from 10 different countries.
Legal Information and Regulation
ES Time is officially registered in Cyprus at Akropoleos 15, Nicosia 1021. The company emphasizes its compliance with regulatory standards and holds partnerships with ASIC, CYSEC, DFSA, FCA, and FSCA. However, specific license details are not publicly available on the platform.
Trading Opportunities with ES Time
ES Time provides access to a diverse range of trading assets, including currencies, cryptocurrencies, metals, commodities, stocks, and indices. The trading platform ensures transaction security, protection against negative balances, and offers various analytical tools. The platform’s interface is user-friendly and compatible across different devices and browsers.
Available Tariff Plans
ES Time offers traders three distinct tariff plans: STANDARD requiring an initial investment of $150, PREMIUM with a minimum deposit of $1,000, and PREMIUM PRO with an initial funding of $10,000. Upon registration, each client receives a dedicated trading account.
Account Management and Withdrawal
Clients at ES Time have the flexibility to withdraw funds at their convenience. However, detailed information regarding available payment services, processing times, applicable fees, and other related conditions are not explicitly provided.
Final Thoughts
Prior to engaging with ES Time, it is advisable to review client testimonials and expert feedback about the company’s services. This will offer valuable insights into the broker’s performance and its commitment to fulfilling obligations towards traders.
This review has been prepared by the specialists at ExpertsReview.